HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer
Myriam Stolz(Medical University of Vienna), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Barbara Neudert(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna), Florian Frommlet(University of Vienna), Kristina Tendl-Schulz(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Maximilian Marhold(Medical University of Vienna), Ruth Exner(Comprehensive Cancer Center Vienna), Ulrike Heber(Comprehensive Cancer Center Vienna), Oskar Koperek(Medical University of Vienna), Alexander Farr(Comprehensive Cancer Center Vienna), H. Reckendorfer(University of Veterinary Medicine Vienna)
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
August 5, 2025
Cited by 1
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Lymph node blood vessels provide exit routes for metastatic tumor cell dissemination in mice
|Science|2018|422